신속 성매개감염병(STI) 검사 시장 규모, 점유율 및 동향 분석 보고서 : 기술별, 감염병 유형별, 검사 유형별, 검체 유형별, 최종 용도별, 지역별 및 부문별 전망(2026-2033년)

Rapid STI Testing Market Summary

The global rapid STI testing market size was valued at USD 1.5 billion in 2025 and is projected to grow from USD 1.6 billion in 2026 to USD 2.8 billion by 2033, at a CAGR of 8.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 41.1% in 2025. Market growth is primarily driven by the rising global burden of sexually transmitted infections, which is increasing demand for rapid, accessible, and timely diagnostic testing

Global Rapid STI Testing Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Single-target Tests has segmented the Rapid STI testing market report on the basis of technology, infection type, test type, sample type, end use and region.

• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Molecular Diagnostics / NAAT
• Rapid Immunoassays
• Others
• Infection Type Outlook (Revenue, USD Million, 2021 - 2033)
• Chlamydia
• Gonorrhea
• SYPHILIS
• TRICHOMONIASIS
• Mycoplasma genitalium
• Multiple STI Targets
• Other STI Targets
• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Single-target Tests
• Multiplex / Combination Tests
• Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
• Urine
• Swab Specimens
• Whole Blood / Serum / Plasma
• Other Specimens
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Diagnostic Laboratories & Near-Point-of-Care Facilities
• Public Health & Community Testing Settings
• Home / Self-testing
• Other End Uses
• Rapid STI Testing Market Regional Outlook (Revenue, USD Million; 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Technology Segment
  • 1.2.2. Infection Type Segment
  • 1.2.3. Test Type Segment
  • 1.2.4. Sample Type Segment
  • 1.2.5. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Global Rapid STI Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Technological Innovation in Rapid STI Diagnostic Technologies and Point-of-Care Testing
    • 3.2.1.2. Growing Global Burden of Sexually Transmitted Infections
    • 3.2.1.3. Increasing Adoption of Decentralized and Point-of-Care STI Testing
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Regulatory, Performance, and Cost Barriers Limiting Rapid STI Testing Adoption
    • 3.2.2.2. Risk of False-Positive and False-Negative Results
  • 3.2.3. Market opportunity analysis
• 3.3. Global Rapid STI Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Global Rapid STI Testing Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Rapid STI Testing Market Technology Movement Analysis
• 4.3. Global Rapid STI Testing Market Size & Trend Analysis by Technology, 2021 to 2033 (USD Million)
• 4.4. Molecular Diagnostics / NAAT
  • 4.4.1. Molecular Diagnostics / NAAT market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Rapid Immunoassays
  • 4.5.1. Rapid Immunoassays market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Global Rapid STI Testing Market: Infection Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Rapid STI Testing Market Infection Type Movement Analysis
• 5.3. Global Rapid STI Testing Market Size & Trend Analysis, by Infection Type, 2021 to 2033 (USD Million)
• 5.4. Chlamydia
  • 5.4.1. Chlamydia market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Gonorrhea
  • 5.5.1. Gonorrhea market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Syphilis
  • 5.6.1. Syphilis market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Trichomoniasis
  • 5.7.1. Trichomoniasis market estimates and forecasts 2021 to 2033 (USD Million)
• 5.8. Mycoplasma genitalium
  • 5.8.1. Mycoplasma genitalium market estimates and forecasts 2021 to 2033 (USD Million)
• 5.9. Multiple STI Targets
  • 5.9.1. Multiple STI Targets market estimates and forecasts 2021 to 2033 (USD Million)
• 5.10. Other
  • 5.10.1. Other market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Global Rapid STI Testing Market: Test Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Rapid STI Testing Market Test Type Movement Analysis
  • 6.2.1. Global Rapid STI Testing Market Size & Trend Analysis, by Test Type, 2021 to 2033 (USD Million)
• 6.3. Single-target Tests
  • 6.3.1. Single-target Tests market estimates and forecasts 2021 to 2033 (USD Million)
• 6.4. Multiplex / Combination Tests
  • 6.4.1. Multiplex / Combination Tests market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Global Rapid STI Testing Market: Sample Type Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Rapid STI Testing Market Sample Type Movement Analysis
  • 7.2.1. Global Rapid STI Testing Market Size & Trend Analysis, by Sample Type, 2021 to 2033 (USD Million)
• 7.3. Urine
  • 7.3.1. Urine market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Swab Specimens
  • 7.4.1. Swab Specimens market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Whole Blood / Serum / Plasma
  • 7.5.1. Whole Blood / Serum / Plasma market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Other Specimens
  • 7.6.1. Other Specimens market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Global Rapid STI Testing Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Rapid STI Testing Market End Use Movement Analysis
  • 8.2.1. Global Rapid STI Testing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 8.3. Hospitals & Clinics
  • 8.3.1. Hospitals & Clinics market estimates and forecasts 2021 to 2033 (USD Million)
• 8.4. Diagnostic Laboratories & Near-Point-of-Care Facilities
  • 8.4.1. Diagnostic Laboratories & Near-Point-of-Care Facilities market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Public Health & Community Testing Settings
  • 8.5.1. Public Health & Community Testing Settings market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Home / Self-testing
  • 8.6.1. Home / Self-testing market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. Other End Uses
  • 8.7.1. Other End Uses market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Rapid STI Testing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Dashboard
• 9.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key country dynamics
    • 9.3.1.2. Regulatory framework/ reimbursement structure
    • 9.3.1.3. Competitive scenario
    • 9.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.2. Canada
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework/ reimbursement structure
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.3.3. Mexico
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework/ reimbursement structure
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework/ reimbursement structure
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework/ reimbursement structure
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework/ reimbursement structure
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework/ reimbursement structure
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework/ reimbursement structure
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.6. Norway
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework/ reimbursement structure
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework/ reimbursement structure
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework/ reimbursement structure
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.4. Australia
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/ reimbursement structure
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework/ reimbursement structure
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework/ reimbursement structure
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.6.2. Argentina
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Company/Competition Categorization
• 10.2. Strategy Mapping
• 10.3. Company Market Share Analysis, 2025
• 10.4. List of Key Certification Providers/Scheme Owners
• 10.5. Company Profiles/Listing
  • 10.5.1. Danaher Corporation
    • 10.5.1.1. Company overview
    • 10.5.1.2. Financial performance
    • 10.5.1.3. Technology benchmarking
    • 10.5.1.4. Strategic initiatives
  • 10.5.2. F. Hoffmann-La Roche Ltd
    • 10.5.2.1. Company overview
    • 10.5.2.2. Financial performance
    • 10.5.2.3. Product benchmarking
    • 10.5.2.4. Strategic initiatives
  • 10.5.3. Abbott
    • 10.5.3.1. Company overview
    • 10.5.3.2. Financial performance
    • 10.5.3.3. Product benchmarking
    • 10.5.3.4. Strategic initiatives
  • 10.5.4. Visby Medical, Inc.
    • 10.5.4.1. Company overview
    • 10.5.4.2. Financial performance
    • 10.5.4.3. Product benchmarking
    • 10.5.4.4. Strategic initiatives
  • 10.5.5. SD Biosensor, INC.
    • 10.5.5.1. Company overview
    • 10.5.5.2. Financial performance
    • 10.5.5.3. Product benchmarking
    • 10.5.5.4. Strategic initiatives
  • 10.5.6. Premier Medical
    • 10.5.6.1. Company overview
    • 10.5.6.2. Financial performance
    • 10.5.6.3. Product benchmarking
    • 10.5.6.4. Strategic initiatives
  • 10.5.7. bioLytical Laboratories Inc.
    • 10.5.7.1. Company overview
    • 10.5.7.2. Financial performance
    • 10.5.7.3. Product benchmarking
    • 10.5.7.4. Strategic initiatives
  • 10.5.8. Biosynex SA
    • 10.5.8.1. Company overview
    • 10.5.8.2. Financial performance
    • 10.5.8.3. Product benchmarking
    • 10.5.8.4. Strategic initiatives
  • 10.5.9. Trinity Biotech plc
    • 10.5.9.1. Company overview
    • 10.5.9.2. Financial performance
    • 10.5.9.3. Product benchmarking
    • 10.5.9.4. Strategic initiatives
  • 10.5.10. Guangzhou Wondfo Biotech Co., Ltd
    • 10.5.10.1. Company overview
    • 10.5.10.2. Financial performance
    • 10.5.10.3. Product benchmarking
    • 10.5.10.4. Strategic initiatives
  • 10.5.11. InTec Products, Inc.
    • 10.5.11.1. Company overview
    • 10.5.11.2. Financial performance
    • 10.5.11.3. Product benchmarking
    • 10.5.11.4. Strategic initiatives
  • 10.5.12. Access Bio, Inc.
    • 10.5.12.1. Company overview
    • 10.5.12.2. Financial performance
    • 10.5.12.3. Product benchmarking
    • 10.5.12.4. Strategic initiatives